Literature DB >> 30819916

A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.

Tiziana D'Agaro1, Antonella Zucchetto1, Filippo Vit1,2, Tamara Bittolo1, Erika Tissino1, Francesca Maria Rossi1, Massimo Degan1, Francesco Zaja3, Pietro Bulian1, Michele Dal Bo1, Simone Ferrero4,5, Marco Ladetto4,6, Alberto Zamò7, Valter Gattei1, Riccardo Bomben8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30819916      PMCID: PMC6717584          DOI: 10.3324/haematol.2018.212811

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.

Authors:  Jiao Ma; Pin Lu; Ailin Guo; Shuhua Cheng; Hongliang Zong; Peter Martin; Morton Coleman; Y Lynn Wang
Journal:  Br J Haematol       Date:  2014-06-24       Impact factor: 6.998

Review 2.  Mantle-cell lymphoma.

Authors:  I Barista; J E Romaguera; F Cabanillas
Journal:  Lancet Oncol       Date:  2001-03       Impact factor: 41.316

3.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Authors:  Jennifer A Woyach; Richard R Furman; Ta-Ming Liu; Hatice Gulcin Ozer; Marc Zapatka; Amy S Ruppert; Ling Xue; Daniel Hsieh-Hsin Li; Susanne M Steggerda; Matthias Versele; Sandeep S Dave; Jenny Zhang; Ayse Selen Yilmaz; Samantha M Jaglowski; Kristie A Blum; Arletta Lozanski; Gerard Lozanski; Danelle F James; Jacqueline C Barrientos; Peter Lichter; Stephan Stilgenbauer; Joseph J Buggy; Betty Y Chang; Amy J Johnson; John C Byrd
Journal:  N Engl J Med       Date:  2014-05-28       Impact factor: 91.245

Review 4.  New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?

Authors:  Martin Dreyling; Simone Ferrero; Niklas Vogt; Wolfram Klapper
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

5.  Improvement of overall survival in advanced stage mantle cell lymphoma.

Authors:  Annina Herrmann; Eva Hoster; Thomas Zwingers; Günter Brittinger; Marianne Engelhard; Peter Meusers; Marcel Reiser; Roswitha Forstpointner; Bernd Metzner; Norma Peter; Bernhard Wörmann; Lorenz Trümper; Michael Pfreundschuh; Hermann Einsele; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

6.  Outcome of deferred initial therapy in mantle-cell lymphoma.

Authors:  Peter Martin; Amy Chadburn; Paul Christos; Karen Weil; Richard R Furman; Jia Ruan; Rebecca Elstrom; Ruben Niesvizky; Scott Ely; Maurizio Diliberto; Ari Melnick; Daniel M Knowles; Selina Chen-Kiang; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

7.  Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Authors:  Rami Rahal; Mareike Frick; Rodrigo Romero; Joshua M Korn; Robert Kridel; Fong Chun Chan; Barbara Meissner; Hyo-eun Bhang; Dave Ruddy; Audrey Kauffmann; Ali Farsidjani; Adnan Derti; Daniel Rakiec; Tara Naylor; Estelle Pfister; Steve Kovats; Sunkyu Kim; Kerstin Dietze; Bernd Dörken; Christian Steidl; Alexandar Tzankov; Michael Hummel; John Monahan; Michael P Morrissey; Christine Fritsch; William R Sellers; Vesselina G Cooke; Randy D Gascoyne; Georg Lenz; Frank Stegmeier
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

8.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Authors:  Michael L Wang; Kristie A Blum; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Liang Zhang; Linda Baher; Mei Cheng; Dana Lee; Darrin M Beaupre; Simon Rule
Journal:  Blood       Date:  2015-06-09       Impact factor: 22.113

Review 9.  How I treat mantle cell lymphoma.

Authors:  Michele Ghielmini; Emanuele Zucca
Journal:  Blood       Date:  2009-06-25       Impact factor: 22.113

10.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.